Faes Farma (FAE.MC) Osake Kurssi
Faes Farma Kurssi
Viimeisten 19 vuoden aikana Faes Farman liikevaihto kasvoi 6,5 % vuodessa ja ylsi 610,46 M EUR:een. Osakekohtainen tulos on kasvanut 2,9 % vuodessa viimeisten 19 vuoden aikana. Faes Farman nettomarginaali 13,0 % on laskenut verrattuna 20,7 %:iin muutama vuosi sitten. Nykyhinnalla osinkotuotto on noin 3,94 %. Jakosuhde on noin 70 % tuloksesta. Osinko on kasvanut 5,5 % vuodessa viimeisten 19 vuoden aikana. Faes Farman 12 kuukauden konsensustavoitehinta on 5,61 EUR, noin yli kurssia 23,4 %. 10 analyytikosta 6 suosittaa ostoa — kokonaiskonsensus on Osta.
Faes Farma osakekurssi
Faes Farma liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Faes Farma -osakkeesta
The business model of Faes Farma SA is focused on the research, development, manufacture, and commercialization of pharmaceutical products. The company specializes in the areas of prescription drugs, hospital medications, and non-prescription drugs. Faes Farma SA operates through a diversified portfolio, catering to various therapeutic areas such as respiratory, dermatology, allergy, and gastrointestinal disorders. The company aims to provide innovative and effective solutions to improve people's health and quality of life. Faes Farma SA's commitment to scientific excellence, strategic partnerships, and continuous product development enables it to meet the evolving needs of patients worldwide.
Faes Farma SA is primarily active in the pharmaceutical industry.
Some of the main competitors of Faes Farma SA in the market include pharmaceutical companies like Grupo Ferrer Internacional, Laboratorios Rubió, Almirall, and Laboratorios Normon.
Faes Farma SA is a leading pharmaceutical company with a rich history and strong background. Established in 1933, Faes Farma has grown steadily over the years to become a key player in the healthcare industry. The company specializes in the research, development, manufacturing, and commercialization of innovative drugs and health products. With a primary focus on respiratory, allergy, and anti-inflammatory treatments, Faes Farma has built a solid reputation for delivering high-quality and effective pharmaceutical solutions. Through continuous innovation and strategic partnerships, the company has successfully expanded its global presence and has become a trusted name in the pharmaceutical sector.
Faes Farma SA, a leading pharmaceutical company, has achieved several significant milestones throughout its history. One notable milestone is the successful development and commercialization of innovative pharmaceutical products. The company has also expanded its market reach globally, establishing a strong presence in various countries. Furthermore, Faes Farma SA has demonstrated continuous growth through strategic partnerships, collaborations, and acquisitions. These milestones reflect the company's commitment to advancing healthcare and delivering quality solutions to customers worldwide. With its relentless dedication and industry expertise, Faes Farma SA has emerged as a prominent player in the pharmaceutical sector, consistently achieving commendable results.
Faes Farma SA is primarily present in Spain and Portugal.
Faes Farma SA represents values and a corporate philosophy centered on innovation, excellence, and commitment to improving healthcare. With a focus on research and development, the company strives to develop high-quality pharmaceutical products that address unmet medical needs. With a long history dating back to 1933, Faes Farma SA emphasizes ethical business practices and sustainable growth. By leveraging its scientific expertise and state-of-the-art technologies, the company aims to provide effective therapies and contribute to the well-being of patients worldwide. Faes Farma SA's dedication to innovation and patient-centric approach makes it a reputable player in the pharmaceutical industry.
Analyytikot asettavat tällä hetkellä Faes Farma-osakkeelle keskimääräisen tavoitehinnan 5,36 EUR (mediaani: 5,61 EUR), mikä merkitsee +17,8 % viimeisimpään hintaan verrattuna. Konsensus perustuu 10 analyytikkoarvioon.
10 analyytikkoa arvioi tällä hetkellä Faes Farma-osaketta: 6 suosittaa ostoa, 3 pitoa ja 1 myyntiä. Vuodelle 2026 analyytikot odottavat Faes Farma-yhtiöltä 758,51 M EUR liikevaihtoa ja 0,32 EUR osakekohtaista tulosta.
Faes Farma-osake (FAE.MC) on listattuna 7 pörssissä, muun muassa: London (0K9H.L), Frankfurt (FFEA.F), München (FFEA.MU), Düsseldorf (FFEA.DU), Madrid (FAE.MC).
Faes Farma SA is a leading pharmaceutical company specializing in the manufacturing and marketing of medicines and medical products. The company was founded in 1933 and is headquartered in Barcelona, Spain. Faes Farma operates in various business areas, including pharmaceutical products, diagnostic and laboratory services, and skincare products. Pharmaceutical products Faes Farma offers a wide range of pharmaceutical products that can be used to treat various diseases and ailments. The company focuses on the development of drugs in the areas of pain medicine, allergology, and respiratory and eye diseases. One outstanding product is Bilastine, an antihistamine used to treat allergic diseases. In 2020, the company generated sales of €136 million with Bilastine. Diagnostic and laboratory services Faes Farma also operates a division for diagnostic and laboratory services. The company offers various tests to detect and treat diseases early. For example, Faes Farma offers a test to determine if a person is suffering from celiac disease. Another example is a test that detects the presence of antibodies against SARS-CoV-2. Skincare products The company also offers a line of skincare products marketed under the brand Bionike. These products have been specifically developed for people with sensitive skin and do not contain questionable ingredients. The product range includes face creams, cleansers, and sunscreens. Faes Farma has a diversified business model based on the development of new products and the expansion into new markets. The company is focused on innovation and invests a significant portion of its sales in research and development every year. Thanks to its innovative capacity and strong market presence, Faes Farma has experienced solid growth in recent years. In 2020, the company had sales of €317.2 million. The size of the company allows for international business expansion. Faes Farma operates in over 80 countries and has a strong presence, particularly in Latin America and Asia.
odotettu liikevaihto Faes Farma on 758,51 M EUR. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Faes Farma on 99,42 M EUR. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Faes Farma:n hinta-voitto-suhde (P/E) on tällä hetkellä 14,23. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Faes Farma-osakkeen arvostusta.
Faes Farma:n hinta-myynti-suhde (P/S) on tällä hetkellä 1,87. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Faes Farma-osakkeen arvostuskennuslukuna.
Faes Farma:n Eulpool-laatuscore on 7/10.
Faes Farma:n ISIN on ES0134950F36. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Faes Farma:n WKN on A0MKAC. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Faes Farma:n ticker on FAE.MC. Tämä pörssinoteeraus käytetään Faes Farma-osakkeiden kauppaan pörssissä.
Faes Farma osake
Faes Farma vertaisryhmä
Faes Farma Ticker
Faes Farma FIGI
Kaikki tunnusluvut ja syvällinen analyysi Faes Farma:sta
Meidän osakeanalyysimme Faes Farma-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Faes Farma:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: